Furthermore, existing FDA-approved, tissue-specific ESR2 modulators, like raloxifene (currently approved for treatment of osteoporosis in post-menopausal women), have been shown to confer neuroprotective effects in a mouse model of epilepsy [80], rendering such drugs as potential candidates for protection of hearing. This evidence concerns the gene ESR2 and osteoporosis.